Skip to content
Nonprofiteer
← All organizations

INTERNATIONAL CANCER ADVOCACY NETWORK

EIN 86-0818253 PHOENIX, AZ

Revenue 2024
$2,722,014
Expenses 2024
$1,230,745

Program services were 91.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

As filed

Subsection
03
NTEE code
T22
Classification
1000
Street
27 W MORTEN AVE

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

Mission

ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-HEME CANCER, PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE US AND ABROAD WITH CUSTOMIZED INFORMATION SERVICES. ICAN ANNUALLY AWARDS R

Activities or mission (Part I)

ICAN ASSISTS STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AS WELL AS ACCESS TO MOLECULAR PROFILING AND CLINICAL TRIALS.

  • PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 360,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, DANA-FARBER CANCER INSTITUTE AND CITY OF HOPE. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS,AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2024-2025 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE AND PRACTICE CHANGING JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, THE PD-L1 AMPLIFIEDS, AND THE NRG1 ENERGIZERS.

    Expenses $679,792 · Grants $360,000

  • PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING FOR THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 22 STATES AND COUNTING); SUPPORTING CO-PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL- FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012.

    Expenses $225,917

  • MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS.

    Expenses $248,520

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • SHERRY WEINSTEIN

    CHAIR-TTEES-

    Total calculated
    $0
    Hours/week
    30

  • MARCIA K HORN JD

    PRESIDENT AN

    Total calculated
    $207,571
    From this org
    $190,000
    From related orgs
    $0
    Other
    $17,571
    Hours/week
    90

    Schedule J breakdown matched by us

    Base
    $190,000
    Bonus
    not reported
    Other
    not reported
    Deferred
    not reported
    Nontaxable benefits
    $17,571
    Filer's total
    $207,571

  • CATHY DALZELL

    CHAIR ADIVIS

    Total calculated
    $0
    Hours/week
    15

  • CHERYL J HINTZEN-GAINES

    CHAIR-HONORA

    Total calculated
    $0
    Hours/week
    3

  • SIDNEY M ROSEN ESQ

    FOUNDING CHA

    Total calculated
    $0
    Hours/week
    10

  • DONNA STONE

    CHAIR, NATIO

    Total calculated
    $0
    Hours/week
    15

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

  • 2024
    Revenue
    $2,722,014
    Expenses
    $1,230,745
    Contributions
    $2,692,996
    Grants paid
    $360,000
  • 2023
    Revenue
    $1,451,316
    Expenses
    $1,027,905
    Contributions
    $1,467,491
    Grants paid
    $300,000
  • 2022
    Revenue
    $1,357,826
    Expenses
    $915,666
    Contributions
    $1,378,104
    Grants paid
    $290,100

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $949,428
    Expenses
    $619,268
    Assets (EOY)
    $2,896,906

  • 2020 · 990

    Revenue
    $983,820
    Expenses
    $601,764
    Assets (EOY)
    $2,574,733

  • 2014 · 990

    Revenue
    $1,227,296
    Expenses
    $388,573
    Assets (EOY)
    $983,096

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Declared on its 2024 return

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Listed as of 13 October 2026, under deductibility PC.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 13 October 2026 and read 23 October 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.